Novo Nordisk India, SKIMS sign MoU to establish CTU

SRINAGAR, DEC 11 – Novo Nordisk India Pvt. Ltd. and Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura have signed a landmark Memorandum of Understanding (MoU) to embark on a strategic collaboration focused on to establish a state-of-the-art Clinical Trial Unit (CTU) for strengthening clinical research in the region, under the aegis of the Department of Clinical Research, SKIMS. This partnership marks a significant milestone for both organizations as they join forces to innovate and transform the clinical research landscape, ultimately aiming to improve patient outcomes. Key dignitaries including Dr. Mohammad Ashraf Ganie, Director, SKIMS & EOSG. Dr. Shariq R. Masoodi, Dean Medical Faculty, SKIMS, Vikrant Shrotriya, Managing Director and Corporate Vice President, Novo Nordisk India Pvt. Ltd, Dr. Maya Sharma, Geetanjli Raghavan, Veranki Leela Bhargavi, Andrey Vasilenko and others. The proceedings of the MOU ceremony was moderated by Dr. Muzaffar Maqsood Wani, Professor of Nephrology, SKIMS emphasized the collaborative potential of this initiative.
Dr. Maya Sharma, Vice President Clinical Medical Regulatory, Novo Nordisk India Pvt. Ltd., said that this partnership underscores our unwavering commitment to redefining the future of clinical research in India. By uniting our global expertise in innovative therapeutics with SKIMS’ exceptional medical infrastructure, we aim to create transformative healthcare solutions. This partnership aspires to bridge gaps in access to advanced medicines, delivering life-changing outcomes for patients in underserved communities and beyond.”  
 Director-SKIMS & EOSG, Dr. Mohammad Ashraf Ganie said that this collaboration represents a significant step towards elevating clinical research standards in the region. By collaborating with Novo Nordisk India Pvt. Ltd., SKIMS aims to contribute to groundbreaking advancements in medical science while ensuring that the people of Jammu and Kashmir have access to world-class healthcare. Dr. Ganie said that this MOU will also pave a way to create a dedicated infrastructure for conducting cutting-edge clinical trials, providing researchers and clinicians with the necessary resources to carry out high-quality research.
 A first of its kind, this MoU for clinical trials with a medical institute in the region, is valid for three years and opens doors to long-term collaboration. The partnership aims to explore groundbreaking solutions in cardiology, obesity, nephrology and rare diseases by leveraging Novo Nordisk’s expertise in developing advanced therapeutics and SKIMS’ robust medical infrastructure. As part of the MoU, Novo Nordisk will contribute to building research capacity by providing resources, clinical research, relevant trainings and project-related equipment. This initiative also aims to enhance the capabilities of the clinical research team at SKIMS, ensuring the outreach of life-saving medicines to larger patient population. Meanwhile, SKIMS will play a pivotal role in expediting the approval process for clinical trials, facilitating patient participation, care and ensuring their safety and convenience.
This collaboration between Novo Nordisk India and SKIMS sets a benchmark for clinical research in the region, reflecting a shared vision to drive innovation and improve healthcare accessibility. By combining global expertise with local insights, this partnership is poised to deliver transformative outcomes for patients, particularly in Jammu and Kashmir. Together, the two organizations aim to pave the way for groundbreaking therapeutic interventions, ensuring that world-class treatments reach those who need them most and setting a strong foundation for future advancements in Indian healthcare.